JP Morgan Maintains Overweight on Protagonist Therapeutics, Lowers Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng has maintained an Overweight rating on Protagonist Therapeutics (NASDAQ:PTGX) but lowered the price target from $36 to $34.
September 25, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Protagonist Therapeutics' price target has been lowered from $36 to $34 by JP Morgan, though the Overweight rating is maintained.
The news of JP Morgan lowering the price target for Protagonist Therapeutics could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Overweight rating indicates that the analyst still sees the stock as a good investment, which could balance out the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100